Olmesartan Medoxomil With HydrochlorothiazideAKM-OLMESARTAN HCTZ
Recommended CardiovascularRestrictedNot applicable line
Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan monotherapy
1
Submissions
2007–07
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2007 Recommended High blood pressure
Access path
- TGA registered · AKM-OLMESARTAN HCTZ
TGA label narrower than the PBS population
- Mar 2007Recommended · restricted
vs olmesartan medoxomil and hydrochlorothiazide taken…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated
Decision context
Populationpatients with hypertension unresponsive to monotherapy with either olmesartan or hydrochlorothiazide
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2007 | Recommended · restricted | olmesartan medoxomil and hydrochlorothiazide taken concomitantly | — | RCT |
Similar precedents
Olmesartan Medoxomil With Amlodipine85%Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide84%Valsartan With Hydrochlorothiazide82%Olmesartan Medoxomil79%Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide76%Amlodipine Besylate With Valsartan74%Telmisartan With Amlodipine72%Perindopril Arginine With Amlodipine Besylate71%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients inadequately controlled on monotherapy; TGA label permits treatment initiation without prior monotherapy failure.